Long-acting Lyotropic Liquid Crystal Technology
Long-acting lyotropic liquid crystal technology is an advanced drug delivery technology based on the self-assembly and phase transition principles of amphiphilic lipids, designed to achieve low initial burst release and high biocompatibility. These formulations offer key advantages, including low-viscosity administration, in situ gel formation after injection, and precise extended release over multiple dosing intervals. The technology is applicable to the development of formulations across multiple therapeutic areas, including chronic disease treatments, long-acting hormone therapies, and oncology products. Bostal has overcome critical technical challenges, such as precise control of liquid crystal phase structures, controllability of in situ phase transition, and maintaining batch-to-batch consistency during scale-up manufacturing. This enables efficient translation of long-acting lyotropic liquid crystal delivery systems from laboratory research to commercial production, accelerating the development and commercialization of innovative long-acting formulations.
